Tenax Therapeutics has received a notice of allowance from the U.S. Patent and Trademark Office (USPTO), indicating that a patent for TNX-103 — oral levosimendan — is to be granted. The patent is expected to cover the use of TNX-103 for treating people with pulmonary hypertension and…
Team PHenomenal Hope will host its inaugural symposium — PHenomenal Hope 2023: Knowledge, Research & Advocacy in PH — on Dec. 15 in Boston, allowing renowned experts, young researchers, and healthcare providers to share efforts on pulmonary hypertension (PH) clinical research and care. “Team PHenomenal Hope has grown…
Treatment with levosimendan — a medication seen to improve cardiac function — was associated with rapid clinical benefits in preterm infants with heart problems and pulmonary hypertension (PH), a study in Germany reports. The response to treatment was independent of the babies’ birth weight and how far along…
Among people with pulmonary arterial hypertension (PAH), a measure of artery deformity called pulmonary artery longitudinal strain may be a predictor of risk of death, a study in Singapore reports. A GLS — or artery global longitudinal strain — below 9% was associated with a higher risk of death. Moreover,…
The Pulmonary Hypertension Association (PHA) will join together with more than 80 organizations worldwide on May 5 for World PH Day, seeking to raise awareness of the global impact of pulmonary hypertension (PH). This year’s theme is “United to Cure PH,” aimed at recognizing the global advances to…
Blood levels of a protein called thrombospondin-2 (TSP2) — related to clinically identifiable measures of right heart structure and function — are consistently increased across patients with different types of pulmonary hypertension (PH), a study in Germany suggests. According to the researchers, these data indicate “that plasma [blood] TSP2…
Tenax Therapeutics is planning to start a Phase 3 clinical trial of TNX-103 — oral levosimendan — to treat pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF) later this year. People with PH-HFpEF have a normal heartbeat, but the heart muscle is too stiff to fill…
A long noncoding RNA molecule (lncRNA) — a long segment of RNA that regulates protein production in the body — may activate or inhibit genes associated with pulmonary arterial hypertension (PAH), according to researchers in China. In their study, a lncRNA was found at higher levels in children with…
Referral to a specialized chronic thromboembolic pulmonary hypertension (CTEPH) center for follow-up treatment after a pulmonary embolism (PE) — a blood clot that blocks an artery in the lungs — is more likely if patients live closer to the center and have access to a primary healthcare provider, a…
The development program of AER-901, Aerami Therapeutics’ inhaled formulation of imatinib, will include pulmonary hypertension associated with interstitial lung disease (PH-ILD). According to the company, data from a completed Phase 1 clinical trial support the progression of AER-901 into Phase 2 trials for pulmonary arterial hypertension (PAH)…
A peptide called apelin-17 may be used as a diagnostic biomarker for idiopathic pulmonary arterial hypertension (IPAH), according to the results of a new study. Apelin-17 levels were found to detect IPAH with an accuracy similar to NT-proBNP and GDF-15 — two established biomarkers for pulmonary hypertension (PH)…
Treatment with swietenine — extracted from the seeds of Swietenia macrophylla, a tree commonly called mahogany — eased the remodeling of lung blood vessels in a mouse model of pulmonary hypertension (PH). Researchers in China found that swietenine worked against this disease hallmark by inhibiting the growth of smooth muscle cells…
Get regular updates to your inbox.